In focus · trending topic

Cyclin Dependent Kinase

16 stories · following the connections

Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

By Nasdaq OMXApr 17, 2018, 1:00 PM UTC

Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

By Nasdaq OMXApr 16, 2018, 11:01 AM UTC

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

By Nasdaq OMXMar 28, 2018, 8:05 PM UTC

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results

By Nasdaq OMXMar 21, 2018, 11:00 AM UTC

Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting

By Nasdaq OMXMar 15, 2018, 11:01 AM UTC

Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

By Nasdaq OMXFeb 6, 2018, 12:01 PM UTC

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

By Nasdaq OMXSep 21, 2017, 11:00 AM UTC

Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results

By Nasdaq OMXAug 9, 2017, 8:06 PM UTC